Paion Ag Aachen (PAIOF) 2.7900 $PAIOF
PAION Founds USA Based Subsidiary and Engages an Experienced U.S. Industry Expert as CEO
Marketwired - Mon Oct 27, 7:04AM CDT
PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3) (XETRA: PA8) will increase its presence in the North American market with the formation of the US-subsidiary PAION Inc. The new company has been established recently and will now start the operational activities under the leadership of Greg Papaz, who will be reporting to Wolfgang Söhngen, CEO of PAION AG and Chairman of the new entity. The office will be located in New Jersey.
Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
Marketwire - Wed Oct 01, 7:02AM CDT
PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3) (FRANKFURT: PA8) announces today that scientific abstracts about clinical data of Remimazolam were accepted for presentation at two major US congresses. The lead investigators will present the clinical results and PAION the hypothetical product profile of its innovative, short acting anaesthetic/sedative to professionals; consisting of gastroenterologists, anaesthetists, surgeons and intensive care professionals. The booth in the commercial exhibition is part of the planned pre-marketing activities.
Sedation Therapeutics Pipeline Review 2014 - 5 Companies & 7 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37hrjp/sedation) has announced the addition of the "Sedation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Paion AG - Maruishi Pharmaceutical Co., Ltd. - NanoMedex Pharmaceuticals, Inc. - Advicenne Pharma Drug Profiles - propofol - ADV-6209 - remimazolam - MR-04A3 - ABP-700 - propofol Microemulsion - clonidine hydrochloride For more information visit http://www.researchandmarkets.com/research/37hrjp/sedation
AZN: 71.43 (+0.67)
Radiation Toxicity Pipeline Review (Radiation Sickness, Acute Radiation Syndrome) - 2013 Edition
M2 - Mon Jun 24, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3jc3b4/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for radiation toxicity , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for radiation toxicity. The report is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: 1. List of Tables/Figures 2. Introduction 2.1 Global Markets Direct Report Coverage 3. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overvi
CVM: 0.65 (-0.02), PSTI: 2.94 (+0.03), NBS: 5.29 (+0.19), OSIR: 13.95 (+0.49), ONTX: 4.58 (+0.16), CBLI: 0.46 (+0.04)
Hemophilia - Pipeline Review, H1 2013
M2 - Fri Apr 05, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/89nnlh/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H1 2013" report to their offering. 'Hemophilia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hemophilia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hemophilia pipeline depth and focus of Indicatio
BIIB: 318.03 (-1.95), PFE: 29.09 (+0.06), SGMO: 12.44 (+0.73), NKTR: 13.94 (+0.46), FLML: 12.88 (+0.16), NVO: 43.50 (-2.30), BAX: 70.32 (+0.47), PTIE: 2.07 (+0.12)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013
M2 - Mon Mar 25, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xpq2c2/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). Scope - A snapshot of the global therapeutic scenario for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). - A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under develo
CVM: 0.65 (-0.02)
PAION Founds USA Based Subsidiary and Engages an Experienced U.S. Industry Expert as CEO
Marketwired - Mon Oct 27, 7:04AM CDT
PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3) (XETRA: PA8) will increase its presence in the North American market with the formation of the US-subsidiary PAION Inc. The new company has been established recently and will now start the operational activities under the leadership of Greg Papaz, who will be reporting to Wolfgang Söhngen, CEO of PAION AG and Chairman of the new entity. The office will be located in New Jersey.
Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014
Marketwire - Wed Oct 01, 7:02AM CDT
PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3) (FRANKFURT: PA8) announces today that scientific abstracts about clinical data of Remimazolam were accepted for presentation at two major US congresses. The lead investigators will present the clinical results and PAION the hypothetical product profile of its innovative, short acting anaesthetic/sedative to professionals; consisting of gastroenterologists, anaesthetists, surgeons and intensive care professionals. The booth in the commercial exhibition is part of the planned pre-marketing activities.
Sedation Therapeutics Pipeline Review 2014 - 5 Companies & 7 Drug Profiles
M2 - Tue Sep 23, 9:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/37hrjp/sedation) has announced the addition of the "Sedation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Sedation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sedation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Paion AG - Maruishi Pharmaceutical Co., Ltd. - NanoMedex Pharmaceuticals, Inc. - Advicenne Pharma Drug Profiles - propofol - ADV-6209 - remimazolam - MR-04A3 - ABP-700 - propofol Microemulsion - clonidine hydrochloride For more information visit http://www.researchandmarkets.com/research/37hrjp/sedation
AZN: 71.43 (+0.67)
Radiation Toxicity Pipeline Review (Radiation Sickness, Acute Radiation Syndrome) - 2013 Edition
M2 - Mon Jun 24, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3jc3b4/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for radiation toxicity , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for radiation toxicity. The report is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: 1. List of Tables/Figures 2. Introduction 2.1 Global Markets Direct Report Coverage 3. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overvi
CVM: 0.65 (-0.02), PSTI: 2.94 (+0.03), NBS: 5.29 (+0.19), OSIR: 13.95 (+0.49), ONTX: 4.58 (+0.16), CBLI: 0.46 (+0.04)
Hemophilia - Pipeline Review, H1 2013
M2 - Fri Apr 05, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/89nnlh/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H1 2013" report to their offering. 'Hemophilia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hemophilia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hemophilia pipeline depth and focus of Indicatio
BIIB: 318.03 (-1.95), PFE: 29.09 (+0.06), SGMO: 12.44 (+0.73), NKTR: 13.94 (+0.46), FLML: 12.88 (+0.16), NVO: 43.50 (-2.30), BAX: 70.32 (+0.47), PTIE: 2.07 (+0.12)
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013
M2 - Mon Mar 25, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xpq2c2/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). Scope - A snapshot of the global therapeutic scenario for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). - A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under develo
CVM: 0.65 (-0.02)
